Craig-Hallum Maintains Indivior(INDV.US) With Buy Rating
Indivior Analyst Ratings
Piper Sandler Maintains Indivior(INDV.US) With Buy Rating, Raises Target Price to $16
Craig-Hallum Maintains Indivior(INDV.US) With Buy Rating
Craig-Hallum Maintains Indivior(INDV.US) With Buy Rating
Craig-Hallum Maintains Indivior(INDV.US) With Buy Rating
Craig-Hallum Maintains Indivior(INDV.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Indivior (GB:INDV), Vor Biopharma (VOR) and Allogene Therapeutics (ALLO)
Stifel Maintains Indivior(INDV.US) With Buy Rating, Cuts Target Price to $18.98
Indivior Analyst Ratings
Craig-Hallum Maintains Indivior(INDV.US) With Buy Rating, Cuts Target Price to $16
Piper Sandler Maintains Indivior(INDV.US) With Buy Rating, Cuts Target Price to $15
Deutsche Bank Maintains Indivior(INDV.US) With Buy Rating, Cuts Target Price to $16.34
Craig-Hallum Maintains Indivior(INDV.US) With Buy Rating
Indivior (INDV) Receives a Buy From Craig-Hallum
Craig-Hallum Maintains Indivior(INDV.US) With Buy Rating
Northland Securities Maintains Indivior(INDV.US) With Buy Rating, Cuts Target Price to $25
Indivior Price Target Maintained With a $22.00/Share by Piper Sandler
Indivior Analyst Ratings
Piper Sandler Maintains Indivior(INDV.US) With Buy Rating, Maintains Target Price $22